{
  "docId": "019dd923-5f69-752d-a9b9-7febd653c093",
  "docSlug": "ZFP1QxeNpCfFhbrzYAWi",
  "documentTitle": "See the 18-slide pitch deck a genetics startup used to raise $100 million and explore the 'dark side' of the genome",
  "authorId": "Pitchdecks",
  "authorName": "CAMP4",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 16,
  "pageCount": 18,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a circular diagram to represent 'Dravet Unmet Needs' surrounded by three key pain points.",
  "elementsJson": [
    "action_title",
    "bullet_list",
    "other"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b9-7febd653c093/16",
  "deckHref": "/decks/019dd923-5f69-752d-a9b9-7febd653c093",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b9-7febd653c093.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b9-7febd653c093#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.28,
        "x": 0.04,
        "y": 0.215
      },
      "kind": "diagram",
      "text": "Dravet Unmet Needs with three surrounding pain points: Limited efficacy, Inability to slow neurodevelop. delay, Current therapies have significant side effect profiles",
      "attrs": null,
      "subkind": "hub-spoke",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d81e51d-335c-4135-970e-35a329a5a3ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.65,
        "x": 0.3,
        "y": 0.25
      },
      "kind": "list",
      "text": "Robust rare disease population – 20K patients in the US and EU; Current treatments (anti-epileptic drugs) act to reduce seizures and vary in terms of efficacy on a per patient basis; Well-organized patient advocacy and KOL community; Disease-modifying therapy may garner pricing in line with Spinraza (SMA, $375K/year)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fdb695d4-63fb-4c6f-b2a1-c6e3d25993be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "TAM: $1B+",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-abe4-75dc-a303-619bf0f78e27",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "$1B+ market opportunity for CAMP4’s targeted SCN1A upregulation approach",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "687d6635-189e-47db-bc0d-d7a9ceff7c54",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 18,
      "from": 13,
      "beatId": "83232633-6fc0-4a1b-a0a5-fe516b3d8578",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The deck presents CAMP4's approach to Dravet and the potential solution offered by their RAP (p13-18)",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 12,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ad824c9f-ade3-46dc-85b3-9835f23c9a9a",
      "evidence": "The deck presents the market opportunity for CAMP4's targeted SCN1A upregulation approach (p16)",
      "position": 0,
      "objective": "Highlight the cost of inaction for Dravet Syndrome patients",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}